Kiss, Lóránd http://orcid.org/0000-0002-9673-6674
Duke, Anna http://orcid.org/0000-0001-5949-391X
Kovacs, Kristof http://orcid.org/0000-0002-7452-067X
Barcza, Tibor
Kiss, Márton http://orcid.org/0000-0001-7010-6511
Petrikovics, Ilona http://orcid.org/0000-0001-7776-4189
Thompson, David E. http://orcid.org/0000-0002-2934-5729
Funding for this research was provided by:
CounterACT Program, National Institutes of Health Office of the Director, and the National Institute of Allergy and Infectious Diseases, NIH/ Department of Defense Interagency Agreement (AOD14020-001-00000/A120-B.P2014-01)
Welch Foundation (X-0011)
Article History
First Online: 6 December 2017
Compliance with Ethical Standards
:
: This research was supported by the CounterACT Program, National Institutes of Health Office of the Director, and the National Institute of Allergy and Infectious Diseases, NIH/Department of Defense Interagency Agreement (AOD14020-001-00000/A120-B.P2014-01), and the Robert A. Welch Foundation (X-0011) at Sam Houston State University, Huntsville, TX, USA. L. Kiss, A. Duke, T. Barcza, M. Kiss, and D.E. Thompson have no known conflicts of interest. Dr. Petrikovics [CitationRef removed, CitationRef removed] is a coauthor of two, and Dr. Kovacs [CitationRef removed] is a coauthor of one, US patents relating to the use of DMTS as a novel cyanide antidote. The authors alone are responsible for the content and writing of the paper.